{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T15:17:31Z","timestamp":1733930251227,"version":"3.30.2"},"reference-count":112,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2024.12765","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T07:11:04Z","timestamp":1731913864000},"source":"Crossref","is-referenced-by-count":0,"title":["Superficial mucoceles as a sequel to Stevens\u2011Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature"],"prefix":"10.3892","volume":"29","author":[{"given":"Vasiliki","family":"Chwia\u0142kowska","sequence":"first","affiliation":[{"name":"Department of Dermatology, Military Institute of Medicine\u2011National Research Institute, Central Clinical Hospital Ministry of Defense, 04\u2011141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"S\u0142owi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Military Institute of Medicine\u2011National Research Institute, Central Clinical Hospital Ministry of Defense, 04\u2011141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"P\u0142atkowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Military Institute of Medicine\u2011National Research Institute, Central Clinical Hospital Ministry of Defense, 04\u2011141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Kania","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Military Institute of Medicine\u2011National Research Institute, Central Clinical Hospital Ministry of Defense, 04\u2011141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Parciak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Military Institute of Medicine\u2011National Research Institute, Central Clinical Hospital Ministry of Defense, 04\u2011141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czarnecka","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska\u2011Curie National Research Institute of Oncology, 02\u2011781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Teterycz","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska\u2011Curie National Research Institute of Oncology, 02\u2011781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Owczarek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Military Institute of Medicine\u2011National Research Institute, Central Clinical Hospital Ministry of Defense, 04\u2011141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"key20241210124625_b1-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"616","DOI":"10.4103\/jomfp.jomfp_470_23","article-title":"Diagnostic challenges of superficial mucoceles: An update","volume":"27","author":"Pandarathodiyil","year":"2023","journal-title":"J Oral Maxillofac Pathol"},{"issue":"3547","key":"key20241210124625_b2-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143547","article-title":"Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group","volume":"13","author":"Hober","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"233","key":"key20241210124625_b3-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03061-6","article-title":"Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: A review of 98 cases","volume":"316","author":"Bray","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"key20241210124625_b4-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/JIR.S454673","article-title":"Emerging insights into stevens-johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy","volume":"17","author":"Lin","year":"2024","journal-title":"J Inflamm Res"},{"key":"key20241210124625_b5-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/imt-2019-0162","article-title":"Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: New cases and a review of the literature","volume":"12","author":"Amy","year":"2020","journal-title":"Immunotherapy"},{"key":"key20241210124625_b6-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3322\/caac.21704","article-title":"The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies","volume":"72","author":"Elad","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"key20241210124625_b7-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"24","DOI":"10.36401\/JIPO-23-14","article-title":"Oral toxicities associated with immune checkpoint inhibitors: Meta-analyses of clinical trials","volume":"7","author":"Srivastava","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"key20241210124625_b8-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.4317\/medoral.25972","article-title":"Superficial mucoceles in cancer patients: A retrospective series from a Stomatology unit","volume":"28","author":"Heguedusch","year":"2023","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"key20241210124625_b9-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/annonc\/mdx640","article-title":"Stevens-Johnson syndrome during nivolumab treatment of NSCLC","volume":"29","author":"Salati","year":"2018","journal-title":"Ann Oncol"},{"issue":"13030\/qt2897t6dq","key":"key20241210124625_b10-ETM-29-1-12765","article-title":"Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer","volume":"27","author":"Gracia-Caza\u00f1a","year":"2021","journal-title":"Dermatol Online J"},{"key":"key20241210124625_b11-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"9428","DOI":"10.3390\/curroncol29120741","article-title":"Nivolumab hypersensitivity reactions a Myth or reality in solid tumors-a systematic review of the literature","volume":"29","author":"P\u00eerlog","year":"2022","journal-title":"Curr Oncol"},{"issue":"13030\/qt97g3t63v","key":"key20241210124625_b12-ETM-29-1-12765","article-title":"Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome","volume":"24","author":"Shah","year":"2018","journal-title":"Dermatol Online J"},{"key":"key20241210124625_b13-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1177\/1078155219830166","article-title":"Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma","volume":"25","author":"Dasanu","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"key20241210124625_b14-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"key20241210124625_b15-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000492172","article-title":"Atezolizumab-Induced stevens-johnson syndrome in a patient with non-small cell lung carcinoma","volume":"10","author":"Chirasuthat","year":"2018","journal-title":"Case Rep Dermatol"},{"issue":"e002521","key":"key20241210124625_b16-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002521","article-title":"T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab","volume":"9","author":"Hammond","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20241210124625_b17-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"issue":"e1214788","key":"key20241210124625_b18-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"issue":"e41439","key":"key20241210124625_b19-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41439","article-title":"Pembrolizumab-associated stevens-johnson syndrome in a patient with metastatic non-small cell lung cancer: A case report","volume":"15","author":"Sandhu","year":"2023","journal-title":"Cureus"},{"issue":"2324709620914796","key":"key20241210124625_b20-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620914796","article-title":"Stevens-Johnson syndrome-like reaction after exposure to pembrolizumab and recombinant zoster vaccine in a patient with metastatic lung cancer","volume":"8","author":"Riano","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"29","key":"key20241210124625_b21-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00261-y","article-title":"A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer","volume":"8","author":"Machida","year":"2022","journal-title":"J Pharm Health Care Sci"},{"key":"key20241210124625_b22-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.12998\/wjcc.v10.i18.6110","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature","volume":"10","author":"Wu","year":"2022","journal-title":"World J Clin Cases"},{"issue":"93","key":"key20241210124625_b23-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00849-5","article-title":"Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab","volume":"19","author":"Lopez","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"key20241210124625_b24-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2018.05.031","article-title":"Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient","volume":"13","author":"Haratake","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"672233","key":"key20241210124625_b25-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.672233","article-title":"Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma","volume":"12","author":"Gianni","year":"2021","journal-title":"Front Pharmacol"},{"key":"key20241210124625_b26-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ajd.14262","article-title":"Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case\/non-case analysis using the Food and Drug Administration Adverse Event Reporting System","volume":"65","author":"Godfrey","year":"2024","journal-title":"Australas J Dermatol"},{"key":"key20241210124625_b27-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"key20241210124625_b28-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1111\/ajd.13704","article-title":"Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma","volume":"63","author":"Zhang","year":"2022","journal-title":"Australas J Dermatol"},{"key":"key20241210124625_b29-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/iju5.12438","article-title":"Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney","volume":"5","author":"Kamei","year":"2022","journal-title":"IJU Case Rep"},{"issue":"146","key":"key20241210124625_b30-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00749-5","article-title":"Case report: A successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies","volume":"14","author":"Li","year":"2023","journal-title":"Discov Oncol"},{"key":"key20241210124625_b31-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: A prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"key20241210124625_b32-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1177\/10781552221074623","article-title":"Cutaneous Stevens Johnson-Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients","volume":"28","author":"Alexandris","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"key20241210124625_b33-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1684\/ejd.2018.3295","article-title":"Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab","volume":"28","author":"Rouyer","year":"2018","journal-title":"Eur J Dermatol"},{"key":"key20241210124625_b34-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1080\/09273948.2021.1896006","article-title":"Pembrolizumab-induced stevens-johnson syndrome with severe ocular complications","volume":"30","author":"Ryu","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"key20241210124625_b35-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.jaip.2023.06.008","article-title":"Nivolumab-induced Stevens-Johnson syndrome: not only due to PD-1 inhibition","volume":"11","author":"Rodr\u00edguez-Otero","year":"2023","journal-title":"J Allergy Clin Immnol Pract"},{"key":"key20241210124625_b36-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during Anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"101290","key":"key20241210124625_b37-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101290","article-title":"SJS\/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color","volume":"50","author":"Pierre","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"key20241210124625_b38-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/DAD.0000000000001527","article-title":"Pembrolizumab-Induced stevens-johnson syndrome\/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: A case report","volume":"42","author":"Robinson","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"key20241210124625_b39-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"449","DOI":"10.14740\/jmc3992","article-title":"Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma","volume":"13","author":"Saad","year":"2022","journal-title":"J Med Cases"},{"key":"key20241210124625_b40-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.21037\/tcr-21-470","article-title":"Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: A case report","volume":"10","author":"Cao","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"23247096211037462","key":"key20241210124625_b41-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211037462","article-title":"A case of guillain-barr\u00e9 syndrome and stevens-johnson syndrome\/toxic epidermal necrosis overlap after pembrolizumab treatment","volume":"9","author":"Oguri","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"key20241210124625_b42-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"key20241210124625_b43-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"key":"key20241210124625_b44-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"key20241210124625_b45-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ccr3.3695","article-title":"Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer","volume":"9","author":"Koshizuka","year":"2020","journal-title":"Clin Case Rep"},{"issue":"949","key":"key20241210124625_b46-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp Ther Med"},{"issue":"e32","key":"key20241210124625_b47-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19031","article-title":"Nivolumab-induced toxic epidermal necrolysis with retiform purpura","volume":"183","author":"Basu","year":"2020","journal-title":"Br J Dermatol"},{"issue":"e9587","key":"key20241210124625_b48-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9587","article-title":"Immune-Mediated toxic epidermal necrolysis","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus"},{"issue":"e15017","key":"key20241210124625_b49-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15017","article-title":"Nivolumab-Induced toxic epidermal necrolysis: Rare but fatal complication of immune checkpoint inhibitor therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Cureus"},{"key":"key20241210124625_b50-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","article-title":"Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma","volume":"4","author":"Griffin","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"13030\/qt8fc428f6","key":"key20241210124625_b51-ETM-29-1-12765","article-title":"Toxic epidermal necrolysis occurring with immune checkpoint inhibitors","volume":"26","author":"Gopee","year":"2020","journal-title":"Dermatol Online J"},{"key":"key20241210124625_b52-ETM-29-1-12765","first-page":"34","article-title":"Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma","volume":"105","author":"Gallo Marin","year":"2022","journal-title":"R I Med J (2013)"},{"key":"key20241210124625_b53-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"589","DOI":"10.25259\/IJDVL_612_2022","article-title":"Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction","volume":"89","author":"Neema","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"key20241210124625_b54-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1097\/CAD.0000000000001162","article-title":"Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis","volume":"33","author":"Kian","year":"2022","journal-title":"Anticancer Drugs"},{"key":"key20241210124625_b55-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1684\/ejd.2022.4378","article-title":"Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as \u2018toxic epidermal necrolysis-like\u2019","volume":"32","author":"Eldani","year":"2022","journal-title":"Eur J Dermatol"},{"key":"key20241210124625_b56-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1159\/000526931","article-title":"Pembrolizumab-Induced Toxic Epidermal Necrolysis","volume":"15","author":"Borg","year":"2022","journal-title":"Case Rep Oncol"},{"issue":"omac025","key":"key20241210124625_b57-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omac025","article-title":"Pembrolizumab-induced toxic epidermal necrolysis: Case report","volume":"2022","author":"Chow","year":"2022","journal-title":"Oxf Med Case Reports"},{"key":"key20241210124625_b58-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/1078155219890659","article-title":"Toxic epidermal necrolysis associated with pembrolizumab","volume":"26","author":"Cai","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"key20241210124625_b59-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20241210124625_b60-ETM-29-1-12765"},{"key":"key20241210124625_b61-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jdv.15770","article-title":"Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus","volume":"34","author":"Yang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20241210124625_b62-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key20241210124625_b63-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/curroncol30070498","article-title":"Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr Oncol"},{"issue":"102574","key":"key20241210124625_b64-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102574","article-title":"Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer","volume":"90","author":"Reike","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"key20241210124625_b65-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"618150","key":"key20241210124625_b66-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618150","article-title":"A phase II Randomized clinical trial and mechanistic studies using improved probiotics to prevent oral mucositis induced by concurrent radiotherapy and chemotherapy in nasopharyngeal carcinoma","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol"},{"issue":"210","key":"key20241210124625_b67-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01715-7","article-title":"Oral mucositis: The hidden side of cancer therapy","volume":"39","author":"Pulito","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"89","key":"key20241210124625_b68-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00089","article-title":"Radiation-Induced oral mucositis","volume":"7","author":"Maria","year":"2017","journal-title":"Front Oncol"},{"issue":"5790","key":"key20241210124625_b69-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245790","article-title":"Oral Mucositis association with periodontal status: A retrospective analysis of 496 patients undergoing hematopoietic stem cell transplantation","volume":"10","author":"Radochov\u00e1","year":"2021","journal-title":"J Clin Med"},{"key":"key20241210124625_b70-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19 (Suppl 1)","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"key20241210124625_b71-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"key20241210124625_b72-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/odi.13964","article-title":"Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Klein","year":"2022","journal-title":"Oral Dis"},{"key":"key20241210124625_b73-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/bjd.14457","article-title":"Delayed oral toxicity from long-term vemurafenib therapy","volume":"174","author":"Lloyd-Lavery","year":"2016","journal-title":"Br J Dermatol"},{"key":"key20241210124625_b74-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjd.18107","article-title":"Resolution of severe oral mucosal changes related to vemurafenib therapy with intensive periodontal treatment","volume":"181","author":"Shephard","year":"2019","journal-title":"Br J Dermatol"},{"key":"key20241210124625_b75-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/jdv.13105","article-title":"Vemurafenib mucosal side-effect","volume":"30","author":"Pileri","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20241210124625_b76-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.4317\/medoral.22470","article-title":"Radiation-related superficial oral mucoceles: An under-recognized acute toxicity in head and neck cancer patients","volume":"23","author":"Prado-Ribeiro","year":"2018","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"key20241210124625_b77-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.joms.2005.11.059","article-title":"Recurrent superficial mucoceles associated with lichenoid disorders","volume":"64","author":"Campana","year":"2006","journal-title":"J Oral Maxillofac Surg"},{"key":"key20241210124625_b78-ETM-29-1-12765","first-page":"E76","article-title":"Superficial oral mucoceles: Description of two cases in patients with graft-versus-host disease","volume":"36","author":"Demarosi","year":"2007","journal-title":"J Otolaryngol"},{"key":"key20241210124625_b79-ETM-29-1-12765","first-page":"82","article-title":"Superficial mucoceles in chronic graft-versus-host disease: A case report and review of the literature","volume":"57","author":"Balasubramaniam","year":"2009","journal-title":"Gen Dent"},{"key":"key20241210124625_b80-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/000155502762064610","article-title":"Superficial mucoceles and lichenoid graft versus host disease: report of three cases","volume":"82","author":"Garc\u00eda-F-Villalta","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"key20241210124625_b81-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.joms.2015.11.025","article-title":"Superficial mucocele of the ventral tongue: Presentation of a rare case and literature review","volume":"74","author":"Brooks","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"issue":"140","key":"key20241210124625_b82-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2021.09.014","article-title":"Palatal superficial mucoceles associated with chronic graft-versus-host disease","volume":"45","author":"Masri","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"key20241210124625_b83-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jdcr.2020.02.041","article-title":"Topical tacrolimus for refractory superficial mucoceles in a patient with chronic graft versus host disease","volume":"6","author":"Deutsch","year":"2020","journal-title":"JAAD Case Rep"},{"key":"key20241210124625_b84-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1034\/j.1600-0714.2001.300304.x","article-title":"The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients","volume":"30","author":"Nicolatou-Galitis","year":"2001","journal-title":"J Oral Pathol Med"},{"key":"key20241210124625_b85-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.oraloncology.2016.03.002","article-title":"Oral superficial mucocele in cancer patients","volume":"56","author":"Zadik","year":"2016","journal-title":"Oral Oncol"},{"key":"key20241210124625_b86-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.4317\/medoral.25629","article-title":"Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria","volume":"28","author":"Pengpis","year":"2023","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"key20241210124625_b87-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cxom.2017.04.006","article-title":"Oral complications of nonsurgical cancer therapies. Atlas Oral Maxillofac Surg. Clin","volume":"25","author":"Elad","year":"2017","journal-title":"North Am"},{"key":"key20241210124625_b88-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/0030-4220(88)90239-3","article-title":"Superficial mucoceles: Pitfall in clinical and microscopic diagnosis","volume":"66","author":"Eveson","year":"1988","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"key20241210124625_b89-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4103\/idoj.idoj_661_21","article-title":"Dermoscopy of oral mucosal lesions: experience from a tertiary care center in north india and review of literature","volume":"13","author":"Rather","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"key20241210124625_b90-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3906\/sag-1907-56","article-title":"Dermoscopy of oral mucocele: Three types of extravasation mucoceles","volume":"50","author":"Ayhan","year":"2020","journal-title":"Turk J Med Sci"},{"issue":"e14478","key":"key20241210124625_b91-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14478","article-title":"Application of mucous membrane dermoscopy (mucoscopy) in diagnostics of benign oral lesions-literature review and preliminary observations from International Dermoscopy Society study","volume":"34","author":"Kumar Jha","year":"2021","journal-title":"Dermatol Ther"},{"issue":"e2021074","key":"key20241210124625_b92-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1103a74","article-title":"Acquired white oral lesions with specific patterns: Oral lichen planus and lupus erythematosus","volume":"11","author":"Manfredini","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"e18038","key":"key20241210124625_b93-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18038","article-title":"Superficial Mucocele: A Rare Presentation","volume":"13","author":"Venugopal","year":"2021","journal-title":"Cureus"},{"issue":"4377","key":"key20241210124625_b94-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154377","article-title":"Minimally Invasive plasma device management of multiple benign skin cancers associated with rare genodermatoses-case series and review of the therapeutic methods","volume":"13","author":"P\u0142atkowska","year":"2024","journal-title":"J Clin Med"},{"key":"key20241210124625_b95-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1111\/jocd.14869","article-title":"Evaluation of skin tissue effects from treatment with a novel hand-held plasma energy device","volume":"21","author":"Holcomb","year":"2022","journal-title":"J Cosmet Dermatol"},{"author":"Bell","key":"key20241210124625_b96-ETM-29-1-12765"},{"key":"key20241210124625_b97-ETM-29-1-12765"},{"key":"key20241210124625_b98-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/1346-8138.12219","article-title":"Case of sunitinib-induced Stevens-Johnson syndrome","volume":"40","author":"Lee","year":"2013","journal-title":"J Dermatol"},{"key":"key20241210124625_b99-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40257-021-00661-0","article-title":"Culprit medications and risk factors associated with stevens-johnson syndrome and toxic epidermal necrolysis: Population-Based nested case-control study","volume":"23","author":"Gronich","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"key20241210124625_b100-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/ijd.13852","article-title":"Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients","volume":"57","author":"Vinay","year":"2018","journal-title":"Int J Dermatol"},{"key":"key20241210124625_b101-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3892\/mco.2018.1553","article-title":"Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient","volume":"8","author":"Yang","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"key20241210124625_b102-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2015.01.018","article-title":"Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer","volume":"88","author":"Koizumi","year":"2015","journal-title":"Lung Cancer"},{"key":"key20241210124625_b103-ETM-29-1-12765"},{"key":"key20241210124625_b104-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15569527.2013.787086","article-title":"Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: New drugs, old side effects","volume":"33","author":"Patrizi","year":"2014","journal-title":"Cutan Ocul Toxicol"},{"key":"key20241210124625_b105-ETM-29-1-12765"},{"issue":"8188","key":"key20241210124625_b106-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098188","article-title":"Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy","volume":"24","author":"Villa","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"954027","key":"key20241210124625_b107-ETM-29-1-12765","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.954027","article-title":"Case report: Alpelisib-induced Stevens-Johnson syndrome","volume":"12","author":"Kurian","year":"2022","journal-title":"Front Oncol"},{"key":"key20241210124625_b108-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30 (Suppl_10)","author":"Nunnery","year":"2019","journal-title":"Ann Oncol"},{"key":"key20241210124625_b109-ETM-29-1-12765"},{"key":"key20241210124625_b110-ETM-29-1-12765","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.15620","article-title":"Dose-limiting stomatitis associated with ibrutinib therapy: A case series","volume":"185","author":"Vigarios","year":"2019","journal-title":"Br J Haematol"},{"key":"key20241210124625_b111-ETM-29-1-12765"},{"key":"key20241210124625_b112-ETM-29-1-12765"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T11:12:51Z","timestamp":1733829171000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2024.12765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,18]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2024.12765","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"type":"print","value":"1792-0981"},{"type":"electronic","value":"1792-1015"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"article-number":"15"}}